Based on the Virtus LifeSci Biotech Clinical Trials ETF stock forecast from 0 analysts, the average analyst target price for Virtus LifeSci Biotech Clinical Trials ETF is not available over the next 12 months. Virtus LifeSci Biotech Clinical Trials ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Virtus LifeSci Biotech Clinical Trials ETF is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Virtus LifeSci Biotech Clinical Trials ETF’s stock price was USD 26.85. Virtus LifeSci Biotech Clinical Trials ETF’s stock price has changed by +1.19% over the past week, -8.69% over the past month and +42.01% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for BBC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
